alendronate / Generic mfg. - LARVOL DELTA

Sodium Alendronate-Modified PLGA-mPEG Nanomicelles Loaded with Rifapentine for Targeted Delivery to Bone Tissue. (PubMed, Pharmaceutics) - "Histopathological analysis indicated no observable pathological alterations in major organs. The ALN-PLGA-mPEG@RPT nanomicelle system exhibits favorable bone-targeting efficiency, sustained-release properties, and biocompatibility, representing a promising strategy for the precise treatment of bone tuberculosis and other skeletal diseases."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Amino-bisphosphonates enhance CD8⁺ T cell responses to vaccine antigens through an ATRAID-dependent mechanism involving the stromal compartment (IMMUNOLOGY 2026) - "Indeed, experiments in mice have shown that BPs can markedly boost humoral immune responses to a variety of antigens. Here, we have examined the effect of alendronate (ALD), a nitrogen containing BP, on the response of CD8+ T cells to immunization with a model vaccine consisting of chicken ovalbumin (OVA) and CpG as an adjuvant. Compared to OVA + CpG alone, the vaccine combined with ALD elicited a significantly higher frequency of effector CD8+ T cells in the spleen and brachial lymph nodes, and these effector cells produced more granzyme B, perforin, TNF-α and IFN-γ... These data indicate that ALD is capable of enhancing the CD8+ T cell response to exogenous antigens by a mechanism that is critically dependent on the presence of ATRAID in the stromal compartment. Off-label combination of BPs with vaccines may potentiate cytotoxic T cell responses."

Stroma • Infectious Disease • Osteoporosis • CD8 • GZMB • IFNG • TNFA

Timing of dental surgery in patients receiving bone-modifying agents: Medication related osteonecrosis of jaw (MRONJ) and implant outcomes in a cohort of 5,284 oncology patients within an integrated dental pathway. (PubMed, J Clin Exp Dent) - "BMAs included intravenous zoledronic acid (n=4,087), subcutaneous denosumab (n=1,187) and oral alendronate (n=10). Dental surgery during or after BMA therapy, even with planned drug holidays, was associated with higher MRONJ and implant loss. Early dental referral and a cautious approach to elective implants after BMA initiation should be standard in oncology supportive care."

Journal • Review • Breast Cancer • Genito-urinary Cancer • Hematological Malignancies • Lung Cancer • Multiple Myeloma • Oncology • Prostate Cancer • Solid Tumor

INCIDENCE, RISK FACTORS AND OUTCOMES OF AVASCULAR NECROSIS IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS DEVELOPING GRAFT-VERSUS-HOST DISEASE (EBMT 2026) - "All patients had hip involvement with median ARCO stage II; 4 had shoulder and 1 had wrist involvement(median number of joints involved: 2,range:1-4).Twelve AVN patients required vitamin D supplementation at diagnosis of AVN, and 13 received bisphosphonates(alendronate:11, zoledronate:2)...AVN cases received higher starting dose of systemic steroids for acute GVHD(median:2.19 vs 1.19 mg/kg prednisolone equivalents, p=0.016), but there were no differences in steroid therapy duration, steroid-refractoriness, or use of maintenance prednisolone and oral budesonide... Symptomatic AVN incidence among ASCT recipients who developed GVHD was 6.4%, with 57% requiring surgery. Higher pre-ASCT steroid exposure, higher initial steroid dose for acute GVHD, higher CD3+ cell dose, and pre-ASCT vitamin D deficiency were potentially modifiable risk factors for AVN."

Clinical • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Lymphoma • Orthopedics • Transplantation

INCIDENCE, RISK FACTORS AND OUTCOMES OF AVASCULAR NECROSIS IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS DEVELOPING GRAFT-VERSUS-HOST DISEASE (EBMT 2026) - "All patients had hip involvement with median ARCO stage II; 4 had shoulder and 1 had wrist involvement(median number of joints involved: 2,range:1-4).Twelve AVN patients required vitamin D supplementation at diagnosis of AVN, and 13 received bisphosphonates(alendronate:11, zoledronate:2)...AVN cases received higher starting dose of systemic steroids for acute GVHD(median:2.19 vs 1.19 mg/kg prednisolone equivalents, p=0.016), but there were no differences in steroid therapy duration, steroid-refractoriness, or use of maintenance prednisolone and oral budesonide... Symptomatic AVN incidence among ASCT recipients who developed GVHD was 6.4%, with 57% requiring surgery. Higher pre-ASCT steroid exposure, higher initial steroid dose for acute GVHD, higher CD3+ cell dose, and pre-ASCT vitamin D deficiency were potentially modifiable risk factors for AVN."

Clinical • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Lymphoma • Orthopedics • Transplantation

LONG-TERM EXPERIENCE TREATING OSTEOPOROSIS WITH DENOSUMAB IN HEMODIALYSIS PATIENTS (ISN-WCN 2026) - "We introduced osteoporosis treatment with alendronate in 2011, ibandronate in 2016, and denosumab in 2018. In a multiple regression analysis, low T-score before treatment and onset of diabetes were significantly associated with the improvement of T-scores.Conclusion The use of denosumab as a treatment of osteoporosis may be effective in hemodialysis patients, especially for the lumbar spine. Low T-score before treatment and onset of diabetes may affect the therapeutic effect."

Clinical • Diabetes • Diabetic Nephropathy • Nephrology • Osteoporosis • Renal Disease • Rheumatology • TRAP

Bond strength and interfacial stability of a universal adhesive to alendronate-treated dentin. (PubMed, Sci Rep) - "It has been concluded that dentin treatment with alendronate specifically 0.3 wt%, before bonding, appeared to enhance bond strength, particularly with etch-and-rinse mode. The results of failure mode analysis, nanoleakage evaluation and micromorphological interface observations confirmed these findings."

Journal

Bisphosphonate and statin: adverse effects of co-medication on wound healing in in vitro models of periodontal tissues. (PubMed, Acta Odontol Scand) - "High concentrations of simvastatin, alone or combined with alendronate, may have a negative impact on angiogenetic markers and cell migration/proliferation, affecting wound healing and growth."

Adverse events • Journal • Preclinical • CASP3 • CXCL8 • IL6

Programmed regulation of microenvironment remodeling and bone regeneration for bone repair by coaxial hydrogel scaffold with ultrasound-activated drug delivery. (PubMed, Mater Today Bio) - "Simultaneously, sustained release of magnesium ions from core layer was achieved by the trapping of alendronate-modified methacrylated gelatin...Furthermore, the cranial defect model revealed that enhanced bone regeneration capacity was realized after implantation of hydrogel scaffold with US treatment through activating the PI3K-Akt signaling pathway to promote bone regeneration. Overall, this study developed an ultrasound-responsive hydrogel scaffold that orchestrated the immune microenvironment and bone regeneration, providing an innovative strategy for effective bone repair."

Journal • Inflammation • IL10

What Is the Role of Alendronate for the Primary and Secondary Prevention of Osteoporotic Fractures in Postmenopausal Women? - A Cochrane Review Summary With Commentary. (PubMed, Int J Rheum Dis) - No abstract available

Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Withdrawal of Alendronate Treatment of Osteoporosis in Rheumatoid Arthritis: Primary findings from the randomised controlled ALOSTRA trial (EULAR 2026) - No abstract available

Clinical • Immunology • Inflammatory Arthritis • Osteoporosis • Rheumatoid Arthritis • Rheumatology

Evaluation of testosterone and alendronate coated membranes in osteoporotic fracture and defect model in rats and goats. (PubMed, J Orthop Translat) - "Early effects are evident in rodents, with later but robust healing in large animal models. The dual anabolic and antiresorptive strategy enhances bone quality and mechanical strength, supporting its potential clinical translation for improving osteoporotic fracture healing."

Journal • Preclinical • CNS Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

A beneficial effect of a novel DKK1 monoclonal antibody and its sequential alendronate on bone and muscle properties of orchiectomized mice. (PubMed, J Orthop Translat) - "This study found that the novel Dkk1-mAb can increase BMD and bone strength, improve bone microarchitecture and muscle performance of orchiectomy-induced osteoporosis mice, and sequential treatment with Dkk1-mAb and alendronate achieves additive benefits. Dkk1-mAb has translational potential for the treatment of osteoporosis."

Journal • Preclinical • Genetic Disorders • Osteoporosis • Rheumatology • DKK1 • LEF1

Upconversion Colloid for Tracking Cellular Uptake of Nanoparticles. (PubMed, Int J Mol Sci) - "The UCC was then PEGylated with PEG-alendronate (PEG-Ale) to facilitate its dispersion in aqueous cell culture media intended for in vitro cell uptake assays...UCC@Ale-PEG was characterized by transmission and scanning electron microscopy, dynamic light scattering, and fluorescence microscopy detecting upconversion photoluminescence emission. The results of an in vitro assay revealed that this new generation of UCC can be internalized by various cell types, including epithelial cells and macrophages, upon several hours of exposure, suggesting broad application potential of this type of UCC in biomedicine, bioengineering, and environmental sciences."

Journal • Brain Cancer • Glioma • Oncology • Solid Tumor

A BONE MARROW-TARGETED NANOMODULATOR AS HISTONE LACTYLATION INHIBITOR FOR REVERSING IMMUNE TOLERANCE OF MULTIPLE MYELOMA (EBMT 2026) - "To enable BM-specific delivery, NanoCURE was coated with hyaluronic acid-alendronate (HA-Ald), allowing it to hijack circulating monocytes/macrophages via HA-CD44 and promote BM homing through alendronate affinity and CXCR4/CXCL12-mediated chemotaxis... Collectively, NanoCURE effectively disrupts the glycolysis–lactate–lactylation cascade and reprograms the BMIM into an immune-reactive niche, offering a potent and targeted strategy to overcome resistance in MM."

IO biomarker • Hematological Malignancies • Multiple Myeloma • CXCL12 • CXCR4 • PKM

A Phase II Randomized Controlled Trial of RAB001 (LLP2A-Alendronate) for Steroid-Induced Early-Stage Osteonecrosis of the Femoral Head (clinicaltrials.gov) - P2 | N=161 | Active, not recruiting | Sponsor: ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd.

New P2 trial

Necrotic-cell-activated macrophages drive an ERK-Bcl-xL survival pathway in osteoclasts and confer bisphosphonate resistance. (PubMed, Biochem Biophys Res Commun) - "Conditioned medium from necrosis-primed macrophages was sufficient to reduce cleaved caspase-3 and maintain osteoclast numbers under alendronate exposure...Collectively, our data indicate that necrosis-primed macrophages drive an ERK-Bcl-xL survival axis in osteoclasts that may underlie the limited therapeutic efficacy of bisphosphonates in ONFH. Targeting macrophage-derived factors or downstream osteoclast survival pathways, potentially in combination with bisphosphonates, may improve therapeutic outcomes."

Journal • Osteoporosis • Rheumatology • BCL2L1 • CASP3

Can P1NP Levels Influence Management Planning for Patients With a Fragility Hip Fracture Receiving Anti-resorptive Medications? (PubMed, Cureus) - " In this selected cohort, measuring pre-operative P1NP levels supported patient-centred multidisciplinary (MDT) bone health planning. Clinicians considered P1NP alongside DXA findings and the broader clinical context when documenting MDT post-fracture bone health plans, with management changes commonly recorded among patients receiving long-term therapy (>5 years). Notably, in this long-term treated group, suppressed P1NP commonly coincided with documented decisions to stop or adjust therapy. Given the retrospective design, small sample size, lack of a comparator group, and absence of outcome data, these findings provide real-world insight into current practice and may support development of a more standardised approach to incorporating P1NP into post-fracture bone health pathways."

Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

A coenzyme-based "interface-welding" hydrogel coating for titanium implants promotes diabetic osseointegration by regulating mitochondrial dynamics. (PubMed, Biomaterials) - "We synthesized p(LA-AcAln) hydrogel through the copolymerization of α-lipoic acid (LA) and acrylated alendronate sodium (AcAln)...In vivo evaluations using a diabetic rat femoral defect model revealed that this coating can significantly improve bone osseointegration. This study not only developed a promising surface modification strategy for orthopedic implants but also provided a viable approach for the treatment of diabetic bone defects and mitochondrial-related orthopedic diseases."

Journal • Diabetes • Metabolic Disorders • Orthopedics

Engineering multifunctional microspheres for sequential regulation of osteoimmune microenvironment and bone remodeling balance to promote regeneration of osteoporotic bone defects. (PubMed, J Orthop Translat) - "Gelatin microspheres grafted with alendronate and loaded with epigallocatechin gallate (Gel@ALN@E) were fabricated via an emulsion-chemical crosslinking method to enable controlled dual-drug release...The composite engineered microsphere system Gel@ALN@E integrates local immunomodulatory and osteoclast-inhibitory functions to directly address key pathological microenvironmental features of osteoporotic bone defects. This integrative design highlights its comprehensive pro-regenerative capacity and provides support for its translational application in the clinical treatment of irregular osteoporotic bone defects."

Journal • Immunology • Inflammation • Osteoporosis • Rheumatology

CLINICAL AND ECONOMIC BENEFITS OF EARLY ROMOSOZUMAB INITIATION IN PATIENTS WITH RECENT OSTEOPOROTIC HIP FRACTURES IN JAPAN (ISPOR 2026) - "The results of our study support that using romosozumab first in the therapeutic sequence, as per Japanese treatment guideline recommendations, is the cost-effective treatment (against delayed romosozumab, vitamin D3, alendronate) with favourable budget impact for patients aged ≥ 50 years with recent osteoporotic hip fractures in Japan."

Clinical • HEOR • Musculoskeletal Diseases • Orthopedics • Osteoporosis

An Approach to Bone Health Optimization in Patients Undergoing Total Joint Arthroplasty (AAOS 2026) - "Of those, 47 patients were started on alendronate by our clinic... Osteoporosis is a modifiable pre-operative risk factor. DEXA screening is significantly underutilized, but incorporating screening into the standard evaluation for TJA patients allows for improved rates of diagnosis and treatment in a population known to be at risk for adverse outcomes. This proactive approach aligns with broader healthcare goals of preventive medicine and patient-centered care."

Clinical • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Preventive care

To evaluate the clinical parameters and bone profile of postmenopausal women from 2022 to 2024 in a menopause outpatient clinic in São Paulo (ISGE 2026) - "When comparing the groups, in relation to the lumbar spine densitometry L1-L4 (T-score), it was observed that women who used hormonal therapy, calcium carbonate and vitamin D had lower bone mass consumption than those who did not use hormonal therapy and used alendronate, calcium and vitamin D."

Clinical

Preclinical assessment of leukocyte- and platelet-rich fibrin for inhibition of mandibular osteonecrosis. (PubMed, Gen Dent) - "Considering that osteonecrosis of the jaw may be due to the antiangiogenic effect of bisphosphonates and that leukocyte- and platelet-rich fibrin (L-PRF) releases proangiogenic factors, this study hypothesized that L-PRF could prevent mandibular osteonecrosis in the surgical alveoli of rats treated with sodium alendronate (ALE) or zoledronic acid (ZOL). In addition, the bone surface had rounded margins and no cells. The results of this study suggest that the presence of L-PRF did not prevent the occurrence of osteonecrosis of the jaw."

Journal • Preclinical

Polycystic Ovarian Syndrome (PCOS): A Brief Overview on Pathogenesis, Main Signaling Pathways, and Recent Studies Performed on Letrozoleinduced PCOS in Rodents. (PubMed, Curr Pharm Biotechnol) - "In addition, several therapeutic approaches and targets that were tested on letrozole-induced PCOS in rodents were summarized and retrieved from the same databases over the past five years. For example, resveratrol, patuletin, adropin, mogroside V, Lepidium sativum seed extract, ascorbic acid, alendronate, probiotics, and mesenchymal stem cells, as well as lifestyle modifications, were shown to have positive effects in the management of PCOS. In conclusion, different approaches have been studied as potential treatments for PCOS according to different disease pathogeneses, molecular pathways, and associated symptoms, showing promising results that might be included in the PCOS therapeutic plan in the future."

Journal • Preclinical • Genetic Disorders • Inflammation • Obesity • Polycystic Ovary Syndrome • KEAP1